Evidence map›Paper›PMID 42003881›Full record

ArticleMolecular therapy. Nucleic acids2026

sgRNA amount is a limiting factor in adenine base editing using RNA LNPs.

Alexandra Birkenshaw, Tyler Thomson, Mai P Truong, Yui Komaki, Nadine Ramsden, Ana Timpano, Cassie Huang, Anna K Blakney, Daniel Z Kurek, Jayesh Kulkarni and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alexandra BirkenshawFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Tyler ThomsonFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Mai P TruongFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Yui KomakiFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Nadine RamsdenFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Ana TimpanoFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Cassie HuangFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Anna K BlakneyMichael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Daniel Z KurekNanoVation Therapeutics, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Jayesh KulkarniNanoVation Therapeutics, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Colin J D RossFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Base editors have emerged as powerful tools for precise genome editing, offering significant therapeutic potential. A critical challenge lies in optimizing the delivery and dosage of single-guide RNA to maximize on-target editing efficiency while minimizing off-target and bystander effects. This study investigates the impact of guide RNA dosage on

Indexed as

ABEadenine base editorbase editingCRISPR/Cas9gene editinggene therapyin vivo gene editinglipid nanoparticlesMT: RNA/DNA Editingon-target editingsgRNAsingle-guide RNAtissue specificity

Identifiers

PMID42003881
PMCPMC13090319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.